Vyne Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel Bd2-Selective Bet Inhibitor Vyn202
vyne therapeutics宣佈第一階段Bd2-選擇性Bet抑制劑Vyn202試驗中第一批參與者的投藥
Vyne Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel Bd2-Selective Bet Inhibitor Vyn202
vyne therapeutics宣佈第一階段Bd2-選擇性Bet抑制劑Vyn202試驗中第一批參與者的投藥
譯文內容由第三人軟體翻譯。